Korea's Health Ministry To Unveil Steeper Price Cuts After Patent Loss; Generics Could Be The Big Loser
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Korea's Ministry of Health and Welfare confirmed that it is preparing a new pricing system to further cut prices of both innovative products and generics. The plan could deal a blow to Korea's generic-dependent pharmas by eventually eliminating price differences of generics and off-patent brands under Korea's national health insurance
You may also be interested in...
Korea Tries To Buffer Heavy Price Cuts With R&D Incentives, But Local And Global Pharma Up In Arms
TOKYO - South Korea's Ministry of Health and Welfare announced this week dual measures to drastically cut drug prices, while also committing to support Korea's innovation-focused companies through tax credits and preferential pricing
Korea Tries To Buffer Heavy Price Cuts With R&D Incentives, But Local And Global Pharma Up In Arms
TOKYO - South Korea's Ministry of Health and Welfare announced this week dual measures to drastically cut drug prices, while also committing to support Korea's innovation-focused companies through tax credits and preferential pricing
Korea Tries To Buffer Heavy Price Cuts With R&D Incentives, But Local And Global Pharma Up In Arms
South Korea's Ministry of Health and Welfare announced measures to drastically cut drug prices, while also committing to support innovation-focused companies through tax credits and preferential pricing, but both domestic and global pharma reacted with strongly worded opposition.